Skip to main content

Table 4 Total and infant sex-stratified adjusted models of androgen levels and 12- and 36-month outcomes

From: Umbilical cord blood androgen levels and ASD-related phenotypes at 12 and 36 months in an enriched risk cohort study

Androgensa

Subject sex

Outcomes

  

12-month AOSI

36-month SRS

  

Beta

95% CI

P

P b

Beta

95% CI

P

P b

ln(T)

Female (n = 62)

0.20

(−0.13,0.53)

0.22

0.95

−0.05

(−0.31,0.20)

0.67

0.85

 

Male (n = 75)

0.22

(−0.13,0.57)

0.22

 

0.14

(−0.19,0.46)

0.41

 

ln(A4)

Female (n = 62)

0.11

(−0.35,0.57)

0.64

0.90

−0.19

(−0.54,0.15)

0.27

0.89

 

Male (n = 75)

0.05

(−0.37,0.47)

0.81

 

−0.17

(−0.55,0.21)

0.38

 

ln(DHEA)

Female (n = 62)

0.1

(−0.18,0.39)

0.48

0.74

−0.04

(−0.26,0.17)

0.70

0.84

 

Male (n = 75)

0.02

(−0.31,0.36)

0.88

 

−0.01

(−0.31,0.32)

0.97

 
  1. ln natural log transformed
  2. aRobust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge (SRS raw) adjusted for gestational age and maternal age. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score
  3. bInteraction P value comes from a model including both subject sexes including covariates, hormone variable, and subject sex hormone interaction